- Home
- CASI vs NXL Comparison
CASI vs NXL Comparison
Compare CASI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- NXL
- Stock Information
- Founded
- CASI 1991
- NXL 2010
- Country
- CASI China
- NXL United States
- Employees
- CASI N/A
- NXL N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- NXL Medical Specialities
- Sector
- CASI Health Care
- NXL Health Care
- Exchange
- CASI Nasdaq
- NXL Nasdaq
- Market Cap
- CASI 20.5M
- NXL 21.0M
- IPO Year
- CASI 1996
- NXL 2022
- Fundamental
- Price
- CASI $1.40
- NXL $1.00
- Analyst Decision
- CASI Strong Buy
- NXL Strong Buy
- Analyst Count
- CASI 1
- NXL 1
- Target Price
- CASI $4.00
- NXL $5.00
- AVG Volume (30 Days)
- CASI 313.5K
- NXL 79.3K
- Earning Date
- CASI 08-15-2025
- NXL 08-07-2025
- Dividend Yield
- CASI N/A
- NXL N/A
- EPS Growth
- CASI N/A
- NXL N/A
- EPS
- CASI N/A
- NXL N/A
- Revenue
- CASI $31,368,000.00
- NXL $131,065.00
- Revenue This Year
- CASI N/A
- NXL $79.59
- Revenue Next Year
- CASI N/A
- NXL $334.65
- P/E Ratio
- CASI N/A
- NXL N/A
- Revenue Growth
- CASI 8.39
- NXL N/A
- 52 Week Low
- CASI $1.09
- NXL $0.59
- 52 Week High
- CASI $7.67
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- CASI 44.81
- NXL 37.97
- Support Level
- CASI $1.23
- NXL $0.96
- Resistance Level
- CASI $1.50
- NXL $1.03
- Average True Range (ATR)
- CASI 0.12
- NXL 0.07
- MACD
- CASI 0.03
- NXL 0.01
- Stochastic Oscillator
- CASI 78.05
- NXL 45.70
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.